To focus on its growing position in emerging markets, Abbott created the Established Pharmaceuticals Division in 2010. The creation of AbbVie In 2011, Abbott announced it was to separate into two ...

Morgan Stanley analyst Terence Flynn raised the firm’s price target on AbbVie (ABBV) to $241 from $239 and keeps an Overweight rating on the ...

Now, after his first year as the pharma’s new CEO, former AbbVie operating chief Robert Michael is captaining a company with few obstacles on the horizon—and picking up a sizable payday for ...